We are live on
!
Find out more
Arbutus Biopharma
ABUS
ABUS
51 hedge funds and large institutions have $173M invested in Arbutus Biopharma in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
2,880% more call options, than puts
Call options by funds: $149K | Put options by funds: $5K
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
2.15% more ownership
Funds ownership: 60% → 62.15% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 53 → 51 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
17% less capital invested
Capital invested by funds: $207M → $173M (-$34.3M)
Holders
51
Holders Change
-2
Holders Change %
-3.77%
% of All Funds
1.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
11
Increased
21
Reduced
13
Closed
13
Calls
$149K
Puts
$5K
Net Calls
+$144K
Net Calls Change
+$172K
Top Buyers
| 1 |
BlackRock
New York
|
+$4.35M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.65M |
| 3 |
Renaissance Technologies
New York
|
+$1.42M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.27M |
| 5 |
Morgan Stanley
New York
|
+$1.21M |
Top Sellers
| 1 |
D.E. Shaw & Co
New York
|
-$3.21M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.39M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.09M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$775K |
| 5 |
RI
RTW Investments
New York
|
-$672K |
